Quantcast

Latest Cystic Fibrosis Foundation Therapeutics Inc. Stories

2014-09-16 08:29:49

Expanded Collaboration Supports Phase 2 Clinical Trial Initiation of First-In-Class ENaC Inhibitor for the Treatment of Cystic Fibrosis DURHAM, N.C., Sept. 16, 2014 /PRNewswire-USNewswire/ -- Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics (CFFT) to support the development of P-1037, Parion's new investigational treatment for cystic fibrosis (CF). This award will accelerate the initiation of a phase 2 trial for P-1037...

2014-06-30 08:30:32

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein. The Phase 3 confirmatory trial is...

2014-05-16 08:26:28

- Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations - SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in % predicted FEV(1) (forced...

2011-07-01 07:00:00

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function. (Logo:...

2010-12-21 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The 48-week study is designed to determine whether ataluren can improve lung function in patients with nmCF. The trial has enrolled 238 patients at 36 sites in North America,...

2010-11-15 07:00:00

SOUTH PLAINFIELD, N.J., Nov. 15, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine. The published data show that treatment with ataluren, an investigational new drug, resulted in statistically significant improvements in the production and function of cystic fibrosis transmembrane...

2010-10-21 10:30:00

MONMOUTH JUNCTION, N.J., Oct. 21 /PRNewswire/ --Transave, Inc., today reported positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis...

2010-09-21 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related